← Leaderboards
Xiaodong Xu
Enantigen Therapeutics, Inc.
$579,817
Attributed
$877,154
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $300K · FY2009–13$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$877,154 · 3
By mechanism
R43$877,154 · 3
Top collaborators
- Ju-Tao Guo2 shared
Most similar at Enantigen Therapeutics, Inc.
Same institution · by research overlap
- Ju-Tao Guo$1,831,311
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelViralExcretory FunctionModificationSeriesToxicity TestsDoseDrug KineticsIn VitroLeadPharmaceutical PreparationsPre-ClinicalBiological AvailabilityToxic EffectAbsorptionDesignAntiviral AgentsClinical TrialsAnimal ModelFrequencies (Time Pattern)In VivoCytotoxicityAnalogCapsid
Grant awards (3)
Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents aga$294,674
R43 · FY2013 · AI · contact PI
Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV Inf$300,000
R43 · FY2012 · AI · contact PI
Development of a Therapy for Dengue Virus Infection$282,480
R43 · FY2009 · AI · contact PI